StageAcquired | Acquired
Diatide, Inc. was founded as a private radiodiagnostic company and in 1999 became Diatide Research Laboratories, a division of Berlex Laboratories focused on developing and making specialized medicines. Diatide was engaged in the imaging marketplace, engaged in peptide engineering, molecular biology and radiolabeling chemistry to develop disease-specific diagnostic and therapeutic agents.
Missing: Diatide's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Diatide's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Diatide Frequently Asked Questions (FAQ)
Where is Diatide's headquarters?
Diatide's headquarters is located at Nine Delta Drive, Londonderry.
What is Diatide's latest funding round?
Diatide's latest funding round is Acquired.
How much did Diatide raise?
Diatide raised a total of $13M.
Who are the investors of Diatide?
Investors of Diatide include Schering-Plough and Alta Partners.
Who are Diatide's competitors?
Competitors of Diatide include iMMCO Diagnostics, ABT Molecular Imaging, Celsense, ContraVac, LipoScience and 13 more.
Compare Diatide to Competitors
At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.
Gold Standard Diagnostics (GSD) provides diagnostic solutions that improve lab efficiency and minimize overall costs. Through an extensive product menu, automated instrument platforms, and outstanding customer service, GSD solves real laboratory problems. The result is a seamless laboratory experience achieved through an integrated approach.
IMMCO Diagnostics provides high-quality diagnostic test kits and lab testing services worldwide for the screening of autoimmune disorders. IMMCO Diagnostics incorporates working on research, clinical laboratory expertise, and medical devices into an approach to autoimmune diagnostics.
Swissray has been recognized as the industry's true pioneer in the design, manufacture and marketing of direct digital Radiography ddR technology. Delivering high quality radiographic images in just seconds, Swissray's single detector technology aims to improve overall productivity, and lowers the cost of general radiography in comparison to conventional or computed radiography.
Cellatope is a cell analysis company that is developing research and diagnostic products and services in the field of autoimmune and inflammatory disease, with an initial focus on lupus and transplant medicine.
Lifelinelab s.r.l. started its activities in April 2003, thanks to the commitment of three managers coming from the ex Diagnostic Division Manufacturing Plant of Alfa Wassermann S.P.A. First step has been to secure raw materials, and equipment for R&D and Manufacturing of products and services in the field of Human in Vitro Diagnostics. nnnnnFirst diagnostic reagents were manufactured, in this site, over 40 years ago, through the bravery and the enterprising spirit of Prof. Balducci ex Managing Director of Virology Laboratory of "Istituto Superiore di Sanitu00e0". First products were based on tissue colture technology included a line of complement fixation antigens. Since then, the company developed methods and products, covering almost all the fields of Human in Vitro Diagnostics, from Clinical Chemistry to Immunochemistry. The mostly developed sector has been that of Infectious Diseases with particular regard to Viral pathologies. Most products have been developed using biological raw materials derived from in house, in vivo or in vitro, productions. Nowadays the company aims to face and develop markets with consolidate and emerging technologies such as Microarrays using a chemistry patented and designed to covalently bind either Protein or Nucleic acids which aims to allow the development of extremely sophisticated analysis in the emerging applications of proteomics and genomics.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.